Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | SCD | O00767 | 6/20 | 0.53 |
| ▸ | RBP4 | P02753 | 2/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25181872 | 0.93 | USP30 (0.53) | EPHX2KDM1ASCDRBP4GPR119 | |
| SCHEMBL3103045 | 0.90 | RBP4 (0.63) | KDM1ARBP4GPR119KDM4E | |
| SCHEMBL31071567 | 0.89 | KDM1A (0.53) | EPHX2KDM1AGPR119KDM4ELMNA | |
| SCHEMBL20570577 | 0.89 | KDM1A (0.53) | EPHX2KDM1ASCDGPR119KDM4E | |
| SCHEMBL3957421 | 0.88 | RBP4 (0.56) | EPHX2SCDRBP4TTR | |
| SCHEMBL22265825 | 0.87 | GPR119 (0.54) | EPHX2KDM1AGPR119 | |
| SCHEMBL21821040 | 0.87 | KDM1A (0.54) | EPHX2KDM1ASCDGPR119KDM4E | |
| SCHEMBL4096764 | 0.85 | KDM1A (0.54) | EPHX2KDM1AGPR119KDM4E | |
| SCHEMBL31726619 | 0.85 | GPR119 (0.62) | KDM1AGPR119 | |
| SCHEMBL20570633 | 0.85 | KDM1A (0.52) | EPHX2KDM1ASCDGPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12268687-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-08 | — | — | US | disclosed |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-30 | — | — | US | disclosed |
| US-12098146-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-09-24 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-11-02 | — | — | US | disclosed |
| CN-116507613-A | Bispecific antagonists of retinol binding protein 4 which stabilize transthyretin tetramer, their preparation and use in the treatment of common age-related complications | 纽约哥伦比亚大学理事会 | 2023-07-28 | — | — | CN | disclosed |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| CN-113906019-A | Compound and use thereof | 优曼尼蒂治疗公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-3914593-A1 | COMPOUNDS AND USES THEREOF | Yumanity Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021097240-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2009117676-A2 | NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| EP-2099793-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-09-16 | — | — | EP | disclosed |
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | MERCK FROSST CANADA LTD. (CA) | 2009-05-07 | — | — | US | disclosed |
| WO-2009012573-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2009-01-29 | — | — | WO | disclosed |
| WO-2008141455-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008064474-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118296-A1 | Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase | SCD, SCD5, SREBF1 | EPHX2 1001/4885KDM1A 2334/4885SCD 1/4885 |
| US-20250034124-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | EPHX2 597/4885KDM1A 1876/4885SCD 3755/4885 |
| US-12268687-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | EPHX2 597/4885KDM1A 1876/4885SCD 3755/4885 |
| US-20230348415-A1 | BISPECIFIC ANTAGONISTS OF RETINOL-BINDING PROTEIN 4 THAT STABILIZE TRANSTHYRETIN TETRAMERS, THEIR PREPARATION, AND USE IN THE TREATMENT OF COMMON AGE-RELATED COMORBIDITIES | TTR, RBP4, RBP1 | EPHX2 2320/4885KDM1A 4682/4885SCD 1580/4885 |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | EPHX2 1094/4885KDM1A 733/4885SCD 1/4885 |
| US-20230116101-A1 | COMPOUNDS AND USES THEREOF | NLN, BDNF, NQO1 | EPHX2 597/4885KDM1A 1876/4885SCD 3755/4885 |
| US-12098146-B2 | Compounds and uses thereof | NLN, BDNF, NQO1 | EPHX2 597/4885KDM1A 1876/4885SCD 3755/4885 |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | EPHX2 2131/4885KDM1A 1172/4885SCD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.